Novo Nordisk (NOVO.B) Stock: The $2 Billion Weight Loss Drug That Just Proved Its Worth

TLDR UBT251 produced mean weight loss of up to 19.7% after 24 weeks in a mid-stage Chinese trial The drug targets three hormones — GLP-1, GIP, and glucagon — earning it the “triple G” label Side effects were mild to moderate and decreased over time Results arrive one day after CagriSema failed to beat Eli [...]

The post Novo Nordisk (NOVO.B) Stock: The $2 Billion Weight Loss Drug That Just Proved Its Worth appeared first on Blockonomi.